Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 380-385

  Hemingway, F ^a   Kashima, T G ^a   Knowles, H J ^a   Athanasou, N A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HVEM; LIGHT; LT R; Osteoclast; RANKL; TRAF

Indexed keywords

CD14 ANTIGEN; HERPESVIRUS ENTRY MEDIATOR LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; HERPESVIRUS ENTRY MEDIATOR; STRESS ACTIVATED PROTEIN KINASE; TNFRSF11A PROTEIN, HUMAN; TNFRSF14 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TNFSF14 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE ATROPHY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; CELL CULTURE; CELL DIFFERENTIATION; DRUG ANTAGONISM; METABOLISM; MONONUCLEAR CELL; OSTEOCLAST; SIGNAL TRANSDUCTION; STEM CELL;

ANTIGENS, CD14; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOCYTES, MONONUCLEAR; LYMPHOTOXIN BETA RECEPTOR; NF-KAPPA B; OSTEOCLASTS; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

MLCS; MLOWN;

EID: 84874474173     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.01.003     Document Type: Article

References (36)

1. Arch R.H., et al. Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes & Development 1998, 12:2821-2830.
2. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
3. Athanasou N.A. The osteoclast-what's new?. Skeletal Radiology 2011, 40:1137-1140.
4. Azuma Y.Y., et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. Journal of Biological Chemistry 2000, 275:4858-4864.
5. Boyle W.J., et al. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
6. Chang Y.H., et al. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells. Journal of Biomedical Science 2005, 12:363-375.
7. Darnay B.G., et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. Journal of Biological Chemistry 1998, 273:20551-20555.
8. Darnay B.G., et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. Journal of Biological Chemistry 1999, 274:7724-7731.
9. Edwards J.R., et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis and Rheumatism 2006, 54:1451-1462.
10. Granger S.W., Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine & Growth Factor Reviews 2003, 14:289-296.
11. Harrop J.A., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. Journal of Biological Chemistry 1998, 273:27548-27556.
12. Heo S.K., et al. NADPH oxidase activation is required for migration by LIGHT in human monocytes. Biochemical and Biophysical Research Communications 2008, 371:834-840.
13. Ishida S., et al. The interaction of monocytes with rheumatoid synovial cells is a key step in LIGHT-mediated inflammatory bone destruction. Immunology 2009, 128:e315-e324.
14. Kaji K.K., et al. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. Journal of Bone and Mineral Research 2001, 16:1593-1599.
15. Kanazawa K., Kudo A. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. Journal of Bone and Mineral Research 2005, 20:840-847.
16. Kanazawa K., et al. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis. Journal of Bone and Mineral Research 2003, 18:443-450.
17. Kang Y.M., et al. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis and Rheumatism 2007, 56:1106-1117.
18. Kawamura N., et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One 2007, 2:e1058.
19. Kim N., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. The Journal of Experimental Medicine 2005, 202:589-595.
20. Knowles H.J., Athanasou N.A. Canonical and non-canonical pathways of osteoclast formation. Histology and Histopathology 2009, 24:337-346.
21. Kobayashi K.K., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. The Journal of Experimental Medicine 2000, 191:275-286.
22. Kudo O.O., et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. The Journal of Pathology 2002, 198:220-227.
23. Lomaga M.A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes & Development 1999, 13:1015-1024.
24. Marsters S.A., et al. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. Journal of Biological Chemistry 1997, 272:14029-14032.
25. Mauri D.N., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
26. Moon J.B., et al. Akt induces osteoclast differentiation through regulating the GSK3/NFATc1 signaling cascade. Journal of Immunology 2011, 188:163-169.
27. Naito A., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes to Cells 1999, 4:353-362.
28. Pasero C., et al. A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production. European Journal of Immunology 2009, 39:2502-2514.
29. Rooney I.A., et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. Journal of Biological Chemistry 2000, 275:14307-14315.
30. Schneider K., et al. Lymphotoxin and LIGHT signaling pathways and target genes. Immunological Reviews 2004, 202:49-66.
31. Shaikh R.B., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. Journal of Immunology 2001, 167:6330-6337.
32. Tanaka S., et al. Signal transduction pathways regulating osteoclast differentiation and function. Journal of Bone and Mineral Metabolism 2003, 21:123-133.
33. Wada T.T., et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends in Molecular Medicine 2006, 12:17-25.
34. Wong B.R., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell 1999, 4:1041-1049.
35. Yang C.R., et al. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death and Differentiation 2004, 11(Suppl. 1):S97-S107.
36. Ye Q., et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. The Journal of Experimental Medicine 2002, 195:795-800.